bupropion SR is one of 279 small molecule programs targeting Cardiovascular Disease. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
583 competitors in Schizophrenia
bupropion SR
Inapsine
Ozempic
Resotran
Zocor
Ibrance
Lunesta
Comtan
Vivarin
Compazine
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Sources
Details